N-11 truncated amyloid-beta Aβ11-x monoclonal antibodies and compositions

Abstract

This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta 11 N-terminal site, i.e. Aβ11-x peptides. It further provides methods of making and using said antibodies, including therapeutic formulations, administration and devices.

What is claimed is: 
     
       1. A monoclonal antibody which specifically binds to a Aβ11-x polypeptide at one or more epitopes present on the first 5 to 7 N-terminal amino acids, wherein said antibody does not specifically bind to a full length Aβ1-40/42 peptide, and wherein the monoclonal antibody is produced by the hybridoma cell with the accession number LMBP 5896CB. 
     
     
       2. A monoclonal antibody which specifically binds to a Aβ11-x polypeptide at one or more epitopes present on the first 5 to 7 N-terminal amino acids, wherein said antibody does not specifically bind to a full length Aβ1-40/42 peptide, and wherein the monoclonal antibody is produced by the hybridoma cell with the accession number LMBP 5897CB. 
     
     
       3. A hybridoma which produces a monoclonal antibody which specifically binds to a Aβ11-x polypeptide at one or more epitopes present on the first 5 to 7 N-terminal amino acids, wherein said antibody does not specifically bind to a full length Aβ1-40/42 peptide, wherein the hybridoma has the accession number LMBP 5896CB. 
     
     
       4. A hybridoma which produces a monoclonal antibody which specifically binds to a Aβ11-x polypeptide at one or more epitopes present on the first 5 to 7 N-terminal amino acids, wherein said antibody does not specifically bind to a full length Aβ1-40/42 peptide, wherein the hybridoma has the accession number LMBP 5897CB.